SG11202110777XA - Treatment of cutaneous lupus erythematosus - Google Patents

Treatment of cutaneous lupus erythematosus

Info

Publication number
SG11202110777XA
SG11202110777XA SG11202110777XA SG11202110777XA SG11202110777XA SG 11202110777X A SG11202110777X A SG 11202110777XA SG 11202110777X A SG11202110777X A SG 11202110777XA SG 11202110777X A SG11202110777X A SG 11202110777XA SG 11202110777X A SG11202110777X A SG 11202110777XA
Authority
SG
Singapore
Prior art keywords
treatment
lupus erythematosus
cutaneous lupus
cutaneous
erythematosus
Prior art date
Application number
SG11202110777XA
Inventor
Jacob Nielsen
Gitte Pommergaard Pedersen
Helene Mortensen
Camilla Sander
Pia Klie Refer
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of SG11202110777XA publication Critical patent/SG11202110777XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202110777XA 2019-05-15 2020-05-14 Treatment of cutaneous lupus erythematosus SG11202110777XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19174586 2019-05-15
PCT/EP2020/063518 WO2020229622A1 (en) 2019-05-15 2020-05-14 Treatment of cutaneous lupus erythematosus

Publications (1)

Publication Number Publication Date
SG11202110777XA true SG11202110777XA (en) 2021-11-29

Family

ID=66554234

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110777XA SG11202110777XA (en) 2019-05-15 2020-05-14 Treatment of cutaneous lupus erythematosus

Country Status (13)

Country Link
US (1) US20220241284A1 (en)
EP (1) EP3968997A1 (en)
JP (1) JP2022533526A (en)
KR (1) KR20220008893A (en)
CN (1) CN113825512A (en)
AU (1) AU2020275208A1 (en)
BR (1) BR112021022031A2 (en)
CA (1) CA3137247A1 (en)
IL (1) IL288011A (en)
MX (1) MX2021012874A (en)
SG (1) SG11202110777XA (en)
TW (1) TW202106690A (en)
WO (1) WO2020229622A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406553A (en) 2022-04-20 2024-02-16 丹麥商理奧藥品公司 Treatment of frontal fibrosing alopecia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (en) 2009-07-31 2015-01-01 Japan Tobacco Inc Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
ES2963784T3 (en) * 2016-01-21 2024-04-02 Leo Pharma As Use of delgocitinib for the treatment of chronic hand eczema

Also Published As

Publication number Publication date
KR20220008893A (en) 2022-01-21
WO2020229622A1 (en) 2020-11-19
MX2021012874A (en) 2021-11-17
AU2020275208A1 (en) 2021-10-28
BR112021022031A2 (en) 2021-12-28
IL288011A (en) 2022-01-01
EP3968997A1 (en) 2022-03-23
TW202106690A (en) 2021-02-16
CN113825512A (en) 2021-12-21
CA3137247A1 (en) 2020-11-19
JP2022533526A (en) 2022-07-25
US20220241284A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
EP3755281C0 (en) Methods for ostomy appliance change and related accessory devices of an ostomy system
GB201804514D0 (en) Treatment of pyroptosis
EP3600374C0 (en) Treatment of respiratory infection
ZA201907401B (en) Treatment of adipocytes
IL270900A (en) Treatment of cutaneous disorders
GB201804515D0 (en) Treatment of necroptosis
ZA201907460B (en) Improved protocol for treatment of lupus nephritis
EP3962869A4 (en) Treatment of fluoride-containing wastewater
IL288011A (en) Treatment of cutaneous lupus erythematosus
EP3458062A4 (en) Treatment of pain
GB201907305D0 (en) Treatment of conditions
EP3863424A4 (en) Addiction treatment of an alcohol-consuming patient population
IL266243A (en) Use of senicapoc for treatment of neuropathic pain
EP4003283C0 (en) Treatment of inflammatory skin conditions
EP3604310A4 (en) Cdc-7-inhibitor compounds and use thereof for the treatment of neurological conditions
AU2018297614A1 (en) Treatment of avascular or hypovascular micro-tumors
GB2575416B (en) Sampling of microorganisms
IL310241A (en) Treatment of lupus
ZA201904327B (en) Treatment of skin conditions
GB201917253D0 (en) Treatment of conditions
PT3790477T (en) Surgical device of repere
IL307750A (en) Treatment of cutaneous lupus erythematous
GB201815000D0 (en) Treatment of hypothroidism and related conditions
GB202001812D0 (en) Point of use device
GB201805556D0 (en) Treatment of ophthalmological conditions